Two 'Golden Ratio' indices in fragment-based drug discovery

被引：45

作者：

Orita, Masaya ^{[1
]}

Ohno, Kazuki ^{[1
]}

Niimi, Tatsuya ^{[1
]}

机构：

[1] Astellas Pharma Inc, Chem Res Labs, Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan

来源：

DRUG DISCOVERY TODAY | 2009年 / 14卷 / 5-6期

关键词：

LEAD GENERATION; LIGAND EFFICIENCY; LIBRARY DESIGN; INHIBITORS; NMR; BINDING; OPTIMIZATION; STRATEGY; SCAFFOLD; POTENT;

D O I：

10.1016/j.drudis.2008.10.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Fragment-based drug discovery (FBDD) is complementary to high-throughput screening. The approach has two key stages: identifying the starting fragment hit to be developed and generating the lead compound from the starting fragment hit. Here, we provide an overview of FBDD and introduce two indices originally developed at Astellas Pharma. The first is related to the size ratio of fragment hits to drug leads; this is useful for fragment-library design and the fragment-to-lead process. The second is related to maximum ligand efficiency; this is useful for fragment hit prioritization and the fragment-to-lead process. Both indices are based on the 'Golden Ratio'.

引用

页码：321 / 328

页数：8

共 41 条

[1] Ligand efficiency indices as guideposts for drug discovery [J].

Abad-Zapatero, C ;

Metz, JT .

DRUG DISCOVERY TODAY, 2005, 10 (07) :464-469

[2] An integrated approach to fragment-based lead generation: Philosophy, strategy and case studies from AstraZeneca's drug discovery programmes [J].

Albert, Jeffrey S. ;

Blomberg, Niklas ;

Breeze, Alexander L. ;

Brown, Alastair J. H. ;

Burrows, Jeremy N. ;

Edwards, Philip D. ;

Folmer, Rutger H. A. ;

Geschwindner, Stefan ;

Griffen, Ed J. ;

Kenny, Peter W. ;

Nowak, Thorsten ;

Olsson, Lise-Lotte ;

Sanganee, Hitesh ;

Shapiro, Adam B. .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (16) :1600-1629

[3] Fragment-based drug discovery: What has it achieved so fair? [J].

Alex, Alexander A. ;

Flocco, Maria M. .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (16) :1544-1567

[4] Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets [J].

Baurin, N ;

Aboul-Ela, F ;

Barril, X ;

Davis, B ;

Drysdale, M ;

Dymock, B ;

Finch, H ;

Fromont, C ;

Richardson, C ;

Simmonite, H ;

Hubbard, RE .

JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 2004, 44 (06) :2157-2166

[5] Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening [J].

Boehm, HJ ;

Boehringer, M ;

Bur, D ;

Gmuender, H ;

Huber, W ;

Klaus, W ;

Kostrewa, D ;

Kuehne, H ;

Luebbers, T ;

Meunier-Keller, N .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (14) :2664-2674

[6]

Bohacek RS, 1996, MED RES REV, V16, P3, DOI 10.1002/(SICI)1098-1128(199601)16:1<3::AID-MED1>3.0.CO

[7]

2-6

[8] Studies leading to potent, dual inhibitors of bcl-2 and Bcl-xL [J].

Bruncko, Milan ;

Oost, Thorsten K. ;

Belli, Barbara A. ;

Ding, Hong ;

Joseph, Mary K. ;

Kunzer, Aaron ;

Martineau, Darlene ;

McClellan, William J. ;

Mitten, Michael ;

ng, Shi-Chu Ng ;

Nimmer, Paul M. ;

Oltersdorf, Tilman ;

Park, Cheol-Min ;

Petros, Andrew M. ;

Shoemaker, Alexander R. ;

Song, Xiaohong ;

Wang, Xilu ;

Wendt, Michael D. ;

Zhang, Haichao ;

Fesik, Stephen W. ;

Rosenberg, Saul H. ;

Elmore, Steven W. .

JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (04) :641-662

[9] A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design [J].

Card, GL ;

Blasdel, L ;

England, BP ;

Zhang, C ;

Suzuki, Y ;

Gillette, S ;

Fong, D ;

Ibrahim, PN ;

Artis, DR ;

Bollag, G ;

Milburn, MV ;

Kim, SH ;

Schlessinger, J ;

Zhang, KYJ .

NATURE BIOTECHNOLOGY, 2005, 23 (02) :201-207

[10] Fragment-based lead discovery: leads by design [J].

Carr, RAE ;

Congreve, M ;

Murray, CW ;

Rees, DC .

DRUG DISCOVERY TODAY, 2005, 10 (14) :987-992

← 1 2 3 4 5 →